



## RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India  
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

April 29, 2016

|                                                                                                                                                                                              |                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| The Manager<br>Listing Department<br>National Stock Exchange of India Limited<br>Exchange Plaza, 5th Floor<br>Plot No. C1, 'G' Block, Bandra-Kurla Complex<br>Bandra (East), Mumbai 400 051. | BSE Limited<br>Floor 25, P.J. Towers<br>Dalal Street<br>Mumbai 400 001. |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|

Dear Sirs,

Sub: Outcome of Board Meeting held on April 29, 2016

(Scrip Code: RPGLIFE / 532983)

This is to inform that the Board of Directors at its meeting held on April 29, 2016 has -


1) approved the enclosed audited financial results for the year ended March 31, 2016.

2) not recommended any dividend.

Kindly take the above on your record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited



Rajesh Shirambekar  
Head - Legal & Company Secretary



Encl: As above



## RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India

Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

| PART I                                                                                    |                |            |            |            |            |
|-------------------------------------------------------------------------------------------|----------------|------------|------------|------------|------------|
| STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2016               |                |            |            |            |            |
| Particulars                                                                               | 3 months ended |            |            | Year ended |            |
|                                                                                           | 31.03.2016     | 31.12.2015 | 31.03.2015 | 31.03.2016 | 31.03.2015 |
|                                                                                           | Unaudited      |            |            | Audited    |            |
| 1. Income from Operations                                                                 |                |            |            |            |            |
| (a) Net Sales/Income from Operations (Net of Excise Duty)                                 | 6,882          | 7,202      | 6,119      | 27,454     | 23,308     |
| (b) Other Operating Income                                                                | 148            | 115        | 557        | 478        | 919        |
| Total Income from Operations (Net)                                                        | 7,030          | 7,317      | 6,676      | 27,932     | 24,227     |
| 2. Expenses                                                                               |                |            |            |            |            |
| (a) Cost of Materials Consumed                                                            | 1,309          | 1,611      | 1,222      | 6,025      | 5,920      |
| (b) Purchases of Stock-in-Trade                                                           | 960            | 741        | 505        | 3,360      | 2,378      |
| (c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade         | (25)           | (74)       | 389        | (241)      | 171        |
| (d) Employee Benefits Expense                                                             | 1,822          | 2,017      | 1,730      | 7,413      | 6,866      |
| (e) Depreciation and Amortisation Expense                                                 | 251            | 247        | 304        | 1,015      | 1,136      |
| (f) Provision for Doubtful Debts and Advances (Net)                                       | 6              | 5          | 63         | 7          | (323)      |
| (g) Other Expenses                                                                        | 2,458          | 2,252      | 1,921      | 9,020      | 7,798      |
| Total Expenses                                                                            | 6,781          | 6,799      | 6,134      | 26,599     | 23,946     |
| 3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items | 249            | 518        | 542        | 1,333      | 281        |
| 4. Other Income                                                                           | 1              | 4          | -          | 78         | 91         |
| 5. Profit/(Loss) from Ordinary Activities before Finance Costs                            | 250            | 522        | 542        | 1,411      | 372        |
| 6. Finance Costs                                                                          | 25             | 55         | 72         | 249        | 272        |
| 7. Profit/(Loss) from Ordinary Activities before Tax                                      | 225            | 467        | 470        | 1,162      | 100        |
| 8. Tax Expense (including Deferred Tax)                                                   | -              | -          | -          | -          | -          |
| 9. Net Profit/(Loss) for the period                                                       | 225            | 467        | 470        | 1,162      | 100        |
| 10. Paid-up Equity Share Capital (Face Value Rs. 8 each)                                  | 1,323          | 1,323      | 1,323      | 1,323      | 1,323      |
| 11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)           |                |            |            | 12,036     | 11,193     |
| 12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):                           |                |            |            |            |            |
| (a) Basic                                                                                 | 1.36           | 2.82       | 1.53       | 7.03       | 0.60       |
| (b) Diluted                                                                               | 1.36           | 2.82       | 1.53       | 7.03       | 0.60       |



*[Handwritten signature]*

Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India

Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127

E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com

CIN : L24232MH2007PLC169354





## RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India  
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

### Notes:

#### 1. Standalone Statement of Assets and Liabilities

| Particulars                                | (Rs. in lakhs)     |                    |
|--------------------------------------------|--------------------|--------------------|
|                                            | As at<br>31.3.2016 | As at<br>31.3.2015 |
| <b>A EQUITY AND LIABILITIES</b>            |                    |                    |
| <b>1. Shareholders' Funds</b>              |                    |                    |
| (a) Share Capital                          | 1,323              | 1,323              |
| (b) Reserves and Surplus                   | 12,036             | 11,193             |
| <b>Sub-total - Shareholders' Funds</b>     | <b>13,359</b>      | <b>12,516</b>      |
| <b>2. Non-Current Liabilities</b>          |                    |                    |
| (a) Long-term Borrowings                   | 24                 | 32                 |
| (b) Deferred Tax Liabilities (Net)         | -                  | -                  |
| (c) Other Long-term Liabilities            | 261                | 266                |
| (d) Long-term Provisions                   | 199                | 158                |
| <b>Sub-total - Non-Current Liabilities</b> | <b>484</b>         | <b>456</b>         |
| <b>3. Current Liabilities</b>              |                    |                    |
| (a) Short-term Borrowings                  | 2,196              | 3,246              |
| (b) Trade Payables                         | 3,371              | 2,530              |
| (c) Other Current Liabilities              | 1,017              | 664                |
| (d) Short-term Provisions                  | 96                 | 279                |
| <b>Sub-total - Current Liabilities</b>     | <b>6,680</b>       | <b>6,719</b>       |
| <b>TOTAL - EQUITY AND LIABILITIES</b>      | <b>20,523</b>      | <b>19,691</b>      |
| <b>B ASSETS</b>                            |                    |                    |
| <b>1. Non-Current Assets</b>               |                    |                    |
| (a) Fixed Assets                           | 11,085             | 10,524             |
| (b) Long-term Loans and Advances           | 719                | 557                |
| <b>Sub-total - Non-Current Assets</b>      | <b>11,804</b>      | <b>11,081</b>      |
| <b>2. Current Assets</b>                   |                    |                    |
| (a) Inventories                            | 3,902              | 3,448              |
| (b) Trade Receivables                      | 3,699              | 4,061              |
| (c) Cash and Bank Balances                 | 80                 | 72                 |
| (d) Short-term Loans and Advances          | 1,038              | 1,029              |
| <b>Sub-total - Current Assets</b>          | <b>8,719</b>       | <b>8,610</b>       |
| <b>TOTAL - ASSETS</b>                      | <b>20,523</b>      | <b>19,691</b>      |

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 29<sup>th</sup> April, 2016.
- The figures for the quarter ended 31st March, 2016 are the balancing figures between the audited financial results for the year ended 31st March, 2016 and the published unaudited financial results for the nine months ended 31st December, 2015.
- The Company is exclusively engaged in the pharmaceuticals segment.
- The Board of Directors at its meeting held on 14th March, 2016 had declared an interim dividend of Rs 1.60 per share of Rs 8/- each (20%) for the Financial year 2015-16 which was paid by the Company on 29th March 2016.
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited



CT. Renganathan  
Managing Director  
Mumbai, 29<sup>th</sup> April, 2016

